Evidence map›Paper›PMID 35394875›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2022

TCR-mimic bispecific antibodies to target the HIV-1 reservoir.

Srona Sengupta, Nathan L Board, Fengting Wu, Milica Moskovljevic, Jacqueline Douglass, Josephine Zhang, Bruce R Reinhold, Jonathan Duke-Cohan, Jeanna Yu, Madison C Reed and 15 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Harnessing αβ T cell receptor mechanobiology to achieve the promise of immuno-oncology.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 1 country.

Srona SenguptaDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Nathan L BoardDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Fengting WuDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0001-6320-8288
Milica MoskovljevicDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Jacqueline DouglassLudwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Josephine ZhangDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Bruce R ReinholdLaboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, MA 02115.
Jonathan Duke-CohanLaboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, MA 02115.ORCID 0000-0002-9478-9609
Jeanna YuDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Madison C ReedDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0002-6425-0717
Yasmine TabdiliDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Aitana AzurmendiDepartment of Biophysics and Biophysical Chemistry, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Emily J FrayDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0002-5850-6237
Hao ZhangDepartment of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205.
Emily Han-Chung HsiueLudwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Katharine JenikeDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Ya-Chi HoDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06519.
Sandra B GabelliDepartment of Biophysics and Biophysical Chemistry, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.ORCID 0000-0003-1205-5204
Kenneth W KinzlerLudwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Bert VogelsteinLudwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Shibin ZhouLudwig Center, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Janet D SilicianoDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Scheherazade Sadegh-NasseriDepartment of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0002-8127-1720
Ellis L ReinherzLaboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, MA 02115.ORCID 0000-0003-1048-5526
Robert F SilicianoDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.ORCID 0000-0002-1764-1993
Johns Hopkins University · USBloomberg (United States) · USHarvard University · USYale University · US

Funding

BIOCHEMISTRY, CELLULAR AND MOLECULAR BIOLOGY PROGRAMT32GM007445 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI GREEN, RACHEL · 1985 to 2021
$24.1M
Medical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4M
Understanding the Impacts of HLA-DO in vivoR01AI120634 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SADEGH-NASSERI, SCHEHERAZADE · 2016 to 2019
$1.6M
Analyzing Non-Classical Antigen Presentation in HIV-infected CD4+ T cellsF30AI136704 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SENGUPTA, SRONA · 2018 to 2020
$150k
Howard Hughes Medical InstituteNIAID NIH HHS F30 AI136704NIAID NIH HHS R01 AI120634NIGMS NIH HHS T32 GM007445NIGMS NIH HHS T32 GM136577
6 · The paper itself

Abstract

HIV-1 infection is incurable due to the persistence of the virus in a latent reservoir of resting memory CD4+ T cells. “Shock-and-kill” approaches that seek to induce HIV-1 gene expression, protein production, and subsequent targeting by the host immune system have been unsuccessful due to a lack of effective latency-reversing agents (LRAs) and kill strategies. In an effort to develop reagents that could be used to promote killing of infected cells, we constructed T cell receptor (TCR)-mimic antibodies to HIV-1 peptide-major histocompatibility complexes (pMHC). Using phage display, we panned for phages expressing antibody-like variable sequences that bound HIV-1 pMHC generated using the common HLA-A*02:01 allele. We targeted three epitopes in Gag and reverse transcriptase identified and quantified via Poisson detection mass spectrometry from cells infected in vitro with a pseudotyped HIV-1 reporter virus (NL4.3 dEnv). Sequences isolated from phages that bound these pMHC were cloned into a single-chain diabody backbone (scDb) sequence, such that one fragment is specific for an HIV-1 pMHC and the other fragment binds to CD3ε, an essential signal transduction subunit of the TCR. Thus, these antibodies utilize the sensitivity of T cell signaling as readouts for antigen processing and as agents to promote killing of infected cells. Notably, these scDbs are exquisitely sensitive and specific for the peptide portion of the pMHC. Most importantly, one scDb caused killing of infected cells presenting a naturally processed target pMHC. This work lays the foundation for a novel therapeutic killing strategy toward elimination of the HIV-1 reservoir.

Indexed as

Antibodies, BispecificHIV-1HIV InfectionsHIV SeropositivityCD4-Positive T-LymphocytesHumansMolecular MimicryReceptors, Antigen, T-CellVirus LatencyAntibodies, BispecificReceptors, Antigen, T-Cellantigen processingHIV-1human leukocyte antigenimmunotherapylatent reservoir

Identifiers

PMID35394875
PMCPMC9169739
OpenAlexW4223505918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.